Trump signs executive order to reclassify marijuana as a Schedule III drug

President Trump signed an executive order directing the attorney general to reschedule marijuana from Schedule I to Schedule III, aiming to lower its federal classification and expedite rulemaking. The move could expand medical research, reduce stigma, attract investment and ease tax restrictions that currently limit deductions for state-licensed cannabis businesses, although recreational use remains federally illegal and political and legal opposition persists. For investors, the action materially improves the regulatory and tax outlook for the cannabis sector but retains uncertainty around implementation, interstate commerce barriers and potential congressional or legal challenges.

Analysis

Market structure: Rescheduling to Schedule III materially improves the economics for US state-licensed cannabis operators by removing (or materially reducing) the 280E tax constraint and lowering banking risk; expect an EBITDA margin uplift concentration in MSOs of ~300–800 bps over 12–24 months as tax deductibility and reduced cash handling costs flow through. Winners are large, capital-market-access MSOs (Curaleaf, Cresco-type operators, MSOS ETF) and ancillary suppliers (Hawthorne/Scotts exposure); losers are illicit market players and small single-state operators that cannot scale. Pricing power will centralize to multi-state operators (MSOs) with distribution scale, accelerating consolidation and lowering unit economics for fragmented players.

Risk assessment: Key tail risks include (1) judicial reversal or Congress blocking Treasury/IRS guidance (low probability but high impact), (2) DEA/DOJ slow rulemaking stretching >12–18 months, and (3) state-level tax policy changes that capture new windfalls. Near-term (days–weeks) volatility will be driven by headlines and option flows; medium-term (3–9 months) depends on formal DEA rulemaking/IRS guidance; long-term (12–36 months) hinges on banking access and interstate commerce policy. Hidden dependencies: lenders’ underwriting standards and FICA/tax code technicals — tax benefits may require explicit IRS regs, not just schedule change.

Trade implications: Tactical trades should target US-focused exposure and optionality: ETFs and deep-liquid names will re-rate faster than OTC microcaps. Expect credit spreads on cannabis financings to compress 100–400 bps if banking access normalizes; municipal revenues in high-tax states could rise modestly. Options: volatility should compress post-rule; use calendar spreads to buy 6–12 month upside convexity while selling nearer-term premium around key regulatory milestones.

Contrarian angles: The market likely overestimates instant banking and interstate commerce unlock — practical normalization may take 6–24 months; early rallies could be reversed if IRS/Treasury delay guidance >90 days. Historical parallel: decriminalization episodes (Portugal, some EU changes) lifted research and M&A but not immediate consumer substitution; expect staged, lumpy re-rating with M&A windows. Unintended consequence: a speeded consolidation could produce losers among mid-tier MSOs that run into capital traps and get bought at low multiples.

Key Decisions for Investors

• Establish a 1.5–3.0% portfolio position long AdvisorShares Pure US Cannabis ETF (MSOS) using a 9–12 month call spread (buy 25–40% OTM call, sell 10–20% nearer-term call) to capture expected 300–800 bps EBITDA margin tailwind while capping premium outlay; reassess after 90 days of regulatory progress.
• Buy TLRY (Tilray Brands) 6–12 month call options (allocate 0.5–1.0% portfolio) 25–40% OTM to capture upside from cross-border M&A and branded CPG partnerships if federal rescheduling accelerates US market entry; size as a volatility directional bet, limit loss to premium paid.
• Implement a pair trade: long MSOS (notional 1–2%) vs short MJ ETF (ETFmg MJ) equal notional for 3–6 months to capture US-specific re-rating versus global/Canadian exposure; close if MSOS outperforms MJ by >15% or if no formal DEA NPRM within 60 days.
• Risk-manage with a time-based stop: reduce cannabis exposure by 50% if DOJ/DEA do not publish a Notice of Proposed Rulemaking (NPRM) or clear IRS guidance within 90 days, and cap single-name OTC exposure at 0.5% until banking relationships are demonstrably available (e.g., two national banks publicly announce cannabis client onboarding).